Video Shorts

0:48
HPV Prevention and Screening Gaps Continue to Drive Anal Cancer Risk
6 months ago
by
Richard Kim, MD

2:46
Luspatercept and Frontline Treatment Decisions in Lower-Risk MDS
6 months ago
by
Jan Bewersdorf, MD, FACP

3:08
OncLive News Roundup for the Week of 3/22
6 months ago
by
Chris Ryan(+1 more)

1:05
BOOM Provides Consensus on Periprosthetic Joint Infection Management in Orthopedic Oncology—but Evidence Gaps Remain
6 months ago
by
R. Lor Randall, MD, FACS

1:08
The Evolution of Axillary Lymph Node Dissection Practices in Breast Cancer
6 months ago
by
La-Urshalar Brock, FNP, BSN, MSN

1:45
What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care
6 months ago
by
Amrita Krishan, MD

1:20
Clinical Equipose When Recommending Individual Clinical Trials
6 months ago
by
Maurie Markman, MD

1:22
Robotics, Cost, and Caution: What’s Actually Advancing Surgical Care in CRC?
6 months ago
by
Marc Lehrer Greenwald, MD

1:13
Precision Medicine Remains the Priority During Multiple Myeloma Awareness Month
6 months ago
by
C. Ola Landgren, MD, PhD

1:22
Missed Signs and Screening Gaps: Why Is Early CRC Detection Falling Short?
6 months ago
by
Jeremy Kortmansky, MD

0:36
Elucidating the Next Steps After EV-Pembro in Urothelial Carcinoma
6 months ago
by
Georges Gebrael, MD

1:27
Exploring the Evolution of ctDNA Testing in Breast Cancer
6 months ago
by
Marla D. Lipsyc-Sharf, MD

0:22
PD-L1 As a Prognostic Biomarker in Penile Cancer
6 months ago
by
Chris Labaki, MD

0:46
Emphasizing the Importance of Considering Different Patient Priorities
6 months ago
by
Sami Diab, MD

0:56
Anal Cancer Care Is Entering a New Era of Precision Medicine and Immunotherapy Use
6 months ago
by
Richard Kim, MD

1:41
Examining Results From the ENVISION Trial in NMIBC
6 months ago
by
Sandip M. Prasad, MD

1:29
Long-Term Goal-Based TKI Treatment Decision-Making for Patients With CML
6 months ago
by
Jorge Cortes, MD

1:00
Targeted Therapies Continue to Reshape Third-Line Treatment Sequencing Decisions in CRC
6 months ago
by
Shubham Pant, MD, MBBS

0:30
ASH Guidelines Provide Key Recommendations in AYA ALL Management
6 months ago
by
Wendy Stock, MD

1:29
Local vs Systemic Therapy for CNS Metastases in Lung Cancer
6 months ago
by
Laura Alder, MD

0:39
Previewing Future Directions for Investigating RSK Inhibition in Breast Cancer
6 months ago
by
Hung T. Khong, MD

2:04
Utilizing MRD Status in Acute Lymphoblastic Leukemia Management
6 months ago
by
Jae Park, MD

1:11
Of mice but not men. Problems of the randomized clinical trial
6 months ago
by
Maurie Markman, MD

1:02
Examining Pasritamig Plus Docetaxel in mCRPC
6 months ago
by
David R. Wise, MD, PhD

0:56
Peptide Receptor Radionucleotide Therapies Gain Momentum in NETs
6 months ago
by
Shubham Pant, MD, MBBS

3:48
OncLive News Roundup for the Week of 3/8
6 months ago
by
Chris Ryan(+1 more)

1:25
Ethics and Identity in Oncology: Clinician vs Investigator
6 months ago
by
Maurie Markman, MD

1:29
Recapping Top Coverage from MBCC 2026!
6 months ago
by
Ashling Wahner (+1 more)

1:59
Navigating Treatment Selection After HMA Failure in Higher-Risk MDS
6 months ago
by
Rami S. Komrokji, MD

0:42
Navigating BTK Inhibitor Data for MCL and Important Next Steps for the Field
6 months ago
by
Tycel Phillips, MD
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Living Guideline for Systemic Treatment of Recurrent Ovarian Cancer
2
OSE2101 Plus Pembrolizumab as Maintenance Boosts PFS in Platinum-Sensitive Ovarian Cancer
3
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 9/14/2026
5
